Navigation Links
Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product
Date:1/5/2012

BRIDGEWATER, N.J., Jan. 5, 2012 /PRNewswire/ -- Sanofi US today announced that the U. S. District Court in Massachusetts granted the company a preliminary injunction against a Synvisc-One® (hylan G-F 20) competitor product developed by Seikagaku Corporation. The ruling allows for a restricted launch of Seikagaku's product prior to a scheduled trial date in April, and prohibits Seikagaku from selling their product below the current average sales price for Synvisc-One.

(Logo:  http://photos.prnewswire.com/prnh/20110616/NY20158LOGO )

In its recent ruling, the Court found that Seikagaku was not likely to prevail at trial, which will focus on U.S. Patent 7,931,030.

"We are pleased that the Court recognized the strength of our '030 patent, which protects Genzyme's Synvisc-One® franchise," said Alison Lawton, Senior Vice President and General Manager of Sanofi's Biosurgery business. "We are also pleased that the Court took decisive steps to protect the market position that Genzyme earned through its research and development and product innovation."

Synvisc-One® has been the only single-injection viscosupplement for the treatment of osteoarthritis (OA) knee pain on the U.S. market since it was launched in the first quarter of 2009.  The market for such treatments is large, growing and underpenetrated; of the estimated 9 million eligible OA patients in the United States, only about 14 percent are currently treated with viscosupplements.

Sanofi's Biosurgery business, which markets a variety of products globally in the areas of osteoarthritis, postoperative adhesion prevention, and cell therapy, is focused on transforming disease management through innovative medical interventions.  It became part of Sanofi following the company's acquisition of Genzyme Corporation in 2011.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as Sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.

Contacts:

US Communications
Kim Fox
+1-908-981-4851
Kimberly.Fox@sanofi.com

Investor Relations
Sebastien Martel
+ 33 153-774-543
sebastien.martel@sanofi-aventis.com


'/>"/>
SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/27/2017)... , ... June 27, 2017 , ... Hammer Strength, the ... (NBSCA) have named Javair Gillett of the Houston Rockets the NBSCA Strength & Conditioning ... award is decided by NBSCA members who vote to select the coach who embodies ...
(Date:6/27/2017)... ... June 27, 2017 , ... East Los Angeles dentist, Ramin ... about early life experiences. What happens to a woman during pregnancy can have profound ... can also take a toll on a baby’s long-term health. This study, which was ...
(Date:6/26/2017)... ... ... Dental Center is now offering various types of dental implants to restore lost teeth. ... prosthetic teeth, such as crowns, bridges, or dentures. An implant is placed directly into the ... for the tooth. , Several types of dental implants are available, including: , ...
(Date:6/26/2017)... ... June 26, 2017 , ... Maryland’s soybean farmers have improved ... released by the United Soybean Board. , Thanks to the responsible use ... their productivity on less land per bushel, the report says. The United Soybean ...
(Date:6/26/2017)... ... June 26, 2017 , ... If ... are seeing lots of red these days. According to recent estimates, 75 – ... from medical coding errors(1). Some studies point to Electronic Health Records (EHR) with ...
Breaking Medicine News(10 mins):